Hutchison Whampoa Pharmaceutical

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases. Headquartered in Hong Kong and with significant operations in mainland China and the United States, the company has successfully brought three self-discovered oncology drugs to market: Elunate (fruquintinib), Sulanda (surufatinib), and Orpathys (savolitinib). Its lead product, fruquintinib, is a highly selective oral inhibitor of VEGFR 1, 2, and 3, which has gained regulatory approval in the U.S., Europe, and China for metastatic colorectal cancer. The company maintains a deep pipeline of clinical-stage candidates and leverages a fully integrated platform encompassing R&D, manufacturing, and a large-scale commercial infrastructure. Strategic collaborations with global partners such as AstraZeneca and Takeda further support the international expansion of its portfolio.